Moderna, Inc. MRNA shares are trading lower on Monday. The stock may be down in sympathy with vaccine peer BioNTech BNTX, which fell after reporting a year-over-year drop in sales and cutting its R&D spending outlook for 2023.
What To Know: BioNTech reported reported €167.70 million ($207.94 million) in sales for the second quarter, a 94.75% decrease over sales of €3.20 billion ($3.96 billion) the same period last year.
BioNTech also reduced its R&D expense outlook to €2-€2.2 billion, down from its prior range of €2.4-€2.6 billion.
Shares of Moderna reacted negatively to BioNTech's earnings report, trading lower by nearly 7% on Monday.
Related Link: What's Going On With Microsoft Monday?
MRNA Price Action: Shares of MRNA were down 6.79% at $100.84 at the time of publication, according to Benzinga Pro.
Image by Triggermouse from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
